We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    D0520C00013
Previous Study | Return to List | Next Study

A Drug-Drug Interaction Study Between AZD9668 and Warfarin to Study the Effect of AZD9668 on the Metabolism and Effect of Warfarin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01214122
Recruitment Status : Withdrawn
First Posted : October 4, 2010
Last Update Posted : January 29, 2013
Sponsor:
Information provided by:

Study Description
Brief Summary:
The primary purpose of this study is to determine whether the treatment with AZD9668 will affect the metabolism and effect of Warfarin.

Condition or disease Intervention/treatment Phase
Pharmacokinetics Pharmacodynamics Drug: AZD9668 Drug: Warfarin Phase 1

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Phase I, Open Label, Fixed Sequence, Single Centre Study in Healthy Volunteers to Investigate the Effects of Repeated Oral Doses AZD9668 on the Pharmacokinetics and Pharmacodynamics of a Single Dose of Warfarin
Study Start Date : November 2010
Estimated Primary Completion Date : December 2010
Estimated Study Completion Date : December 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Thinners
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Treatment A
AZD9668 - 2 x30mg tablets
Drug: AZD9668
60 mg orally twice daily for 11 days
Experimental: Treatment B
Warfarin - 10 x2.5 mg tablets
Drug: Warfarin
10 x 2.5 (25) mg orally once daily on day 1 and on day 14


Outcome Measures

Primary Outcome Measures :
  1. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC) [ Time Frame: Pharmacokinetic (PK) sampling will be performed day 1 ]
  2. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC) [ Time Frame: Pharmacokinetic (PK) sampling will be performed day 2 ]
  3. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC) [ Time Frame: Pharmacokinetic (PK) sampling will be performed day 3 ]
  4. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC) [ Time Frame: Pharmacokinetic (PK) sampling will be performed day 4 ]
  5. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC) [ Time Frame: Pharmacokinetic (PK) sampling will be performed day 5 ]
  6. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC) [ Time Frame: Pharmacokinetic (PK) sampling will be performed day 6 ]
  7. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC) [ Time Frame: Pharmacokinetic (PK) sampling will be performed day 7 ]
  8. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC) [ Time Frame: Pharmacokinetic (PK) sampling will be performed day 8 ]
  9. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC) [ Time Frame: Pharmacokinetic (PK) sampling will be performed day 9 ]
  10. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC) [ Time Frame: Pharmacokinetic (PK) sampling will be performed day 10 ]
  11. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC) [ Time Frame: Pharmacokinetic (PK) sampling will be performed day 11 ]
  12. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC) [ Time Frame: Pharmacokinetic (PK) sampling will be performed day 12 ]
  13. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC) [ Time Frame: Pharmacokinetic (PK) sampling will be performed day 13 ]
  14. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC) [ Time Frame: Pharmacokinetic (PK) sampling will be performed day 14 ]
  15. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC) [ Time Frame: Pharmacokinetic (PK) sampling will be performed day 15 ]
  16. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC) [ Time Frame: Pharmacokinetic (PK) sampling will be performed day 16 ]
  17. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC) [ Time Frame: Pharmacokinetic (PK) sampling will be performed day 17 ]
  18. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC) [ Time Frame: Pharmacokinetic (PK) sampling will be performed day 18 ]
  19. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC) [ Time Frame: Pharmacokinetic (PK) sampling will be performed day 19 ]
  20. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC) [ Time Frame: Pharmacokinetic (PK) sampling will be performed day 20 ]
  21. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC) [ Time Frame: Pharmacokinetic (PK) sampling will be performed day 21 ]
  22. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC) [ Time Frame: Pharmacokinetic (PK) sampling will be performed day 22 ]
  23. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC) [ Time Frame: Pharmacokinetic (PK) sampling will be performed day 23 ]
  24. Pharmacodynamics measured by maximum international normalised ratio ( INRmax) [ Time Frame: International normalised ratio (INR) sampling will be performed day 1 ]
  25. Pharmacodynamics measured by maximum international normalised ratio ( INRmax) [ Time Frame: International normalised ratio (INR) sampling will be performed day 2 ]
  26. Pharmacodynamics measured by maximum international normalised ratio ( INRmax) [ Time Frame: International normalised ratio (INR) sampling will be performed day 3 ]
  27. Pharmacodynamics measured by maximum international normalised ratio ( INRmax) [ Time Frame: International normalised ratio (INR) sampling will be performed day 4 ]
  28. Pharmacodynamics measured by maximum international normalised ratio ( INRmax) [ Time Frame: International normalised ratio (INR) sampling will be performed day 5 ]
  29. Pharmacodynamics measured by maximum international normalised ratio ( INRmax) [ Time Frame: International normalised ratio (INR) sampling will be performed day 6 ]
  30. Pharmacodynamics measured by maximum international normalised ratio ( INRmax) [ Time Frame: International normalised ratio (INR) sampling will be performed day 7 ]
  31. Pharmacodynamics measured by maximum international normalised ratio ( INRmax) [ Time Frame: International normalised ratio (INR) sampling will be performed day 8 ]
  32. Pharmacodynamics measured by maximum international normalised ratio ( INRmax) [ Time Frame: International normalised ratio (INR) sampling will be performed day 9 ]
  33. Pharmacodynamics measured by maximum international normalised ratio ( INRmax) [ Time Frame: International normalised ratio (INR) sampling will be performed day 10 ]
  34. Pharmacodynamics measured by maximum international normalised ratio ( INRmax) [ Time Frame: International normalised ratio (INR) sampling will be performed day 11 ]
  35. Pharmacodynamics measured by maximum international normalised ratio ( INRmax) [ Time Frame: International normalised ratio (INR) sampling will be performed day 12 ]
  36. Pharmacodynamics measured by maximum international normalised ratio ( INRmax) [ Time Frame: International normalised ratio (INR) sampling will be performed day 13 ]
  37. Pharmacodynamics measured by maximum international normalised ratio ( INRmax) [ Time Frame: International normalised ratio (INR) sampling will be performed day 14 ]
  38. Pharmacodynamics measured by maximum international normalised ratio ( INRmax) [ Time Frame: International normalised ratio (INR) sampling will be performed day 15 ]
  39. Pharmacodynamics measured by maximum international normalised ratio ( INRmax) [ Time Frame: International normalised ratio (INR) sampling will be performed day 16 ]
  40. Pharmacodynamics measured by maximum international normalised ratio ( INRmax) [ Time Frame: International normalised ratio (INR) sampling will be performed day 17 ]
  41. Pharmacodynamics measured by maximum international normalised ratio ( INRmax) [ Time Frame: International normalised ratio (INR) sampling will be performed day 18 ]
  42. Pharmacodynamics measured by maximum international normalised ratio ( INRmax) [ Time Frame: International normalised ratio (INR) sampling will be performed day 19 ]
  43. Pharmacodynamics measured by maximum international normalised ratio ( INRmax) [ Time Frame: International normalised ratio (INR) sampling will be performed day 20 ]
  44. Pharmacodynamics measured by maximum international normalised ratio ( INRmax) [ Time Frame: International normalised ratio (INR) sampling will be performed day 21 ]
  45. Pharmacodynamics measured by maximum international normalised ratio ( INRmax) [ Time Frame: International normalised ratio (INR) sampling will be performed day 22 ]
  46. Pharmacodynamics measured by maximum international normalised ratio ( INRmax) [ Time Frame: International normalised ratio (INR) sampling will be performed day 23 ]

Secondary Outcome Measures :
  1. Pharmacokinetics for AZD9668 measured by Css,max [ Time Frame: Range from day 9 to 23 ]
  2. Pharmacokinetics for AZD9668 measured by tss,max [ Time Frame: Range from day 9 to 23 ]
  3. Pharmacokinetics for AZD9668 measured by Css,min [ Time Frame: Range from day 9 to 23 ]
  4. Pharmacokinetics for AZD9668 measured by CLss/F [ Time Frame: Range from day 9 to 23 ]
  5. Severity of Adverse Events as a Measure of Safety and Tolerability [ Time Frame: Adverse events will be collected pre-dose, during treatment and at follow up ]
  6. Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: Adverse events will be collected pre-dose, during treatment and at follow up ]
  7. Pharmacokinetics for (R)- and (S)- Warfarin measured tmax. [ Time Frame: Range from day 1 to 23 ]
  8. Pharmacokinetics for (R)- and (S)- Warfarin measured t½. [ Time Frame: Range from day 1 to 23 ]
  9. Pharmacokinetics for (R)- and (S)- Warfarin measured CL/F. [ Time Frame: Range from day 1 to 23 ]
  10. Pharmacokinetics for (R)- and (S)- Warfarin measured Vz/F. [ Time Frame: Range from day 1 to 23 ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Provision of signed informed consent (including genotyping screening sample for CYP2C9 and VKORC1) prior to any study specific procedures
  • Subjects must be willing to use a barrier method of contraception, unless their partners are post-menopausal or surgically sterile, or if a female partner is of childbearing potential the subject must use a barrier method of contraception (condom) and the partner must use accepted contraceptive methods (oral contraceptive, implant, long term injectable contraceptive or intrauterine device), from first dose of IP (warfarin and AZD9668) until 3 months after last dose of IP (warfarin and AZD9668)
  • Have a body mass index between 19 and 30 kg/m2 (inclusive) and a weight between 50 and 100 kg (inclusive)
  • Be a non-smoker or ex-smoker who has stopped smoking for >6 months prior to Visit 1.

Exclusion Criteria:

  • Any clinically significant disease or disorder
  • Subject predicted to have high sensitivity to warfarin based on CYP2C9 and VKORC1 genotypes
  • Any clinically relevant abnormal findings in physical examination
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01214122


Locations
Sweden
Research Site
Linköping, Sweden
Research Site
Uppsala, Sweden
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Christopher D O'Brien, MD, PhD AstraZeneca R&D
Principal Investigator: Ingemar Bylesjö, MD Berzelius Clinical Reseach Centre
Principal Investigator: Wolfgang Kühn, MD Quintiles AB, Phase 1 Services
More Information

Responsible Party: Medical Science Director, AstraZeneca
ClinicalTrials.gov Identifier: NCT01214122     History of Changes
Other Study ID Numbers: D0520C00013
2010-022360-12 ( EudraCT Number )
First Posted: October 4, 2010    Key Record Dates
Last Update Posted: January 29, 2013
Last Verified: January 2013

Keywords provided by AstraZeneca:
Phase 1
Drug-Drug interaction
warfarin
AZD9668
resulting from AZD9668 and Warfarin interaction
pharmacokinetics
pharmacodynamics

Additional relevant MeSH terms:
Warfarin
Anticoagulants